Melphalan and cladribine before transplant for AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two chemotherapy drugs, melphalan and cladribine, given before a stem cell transplant. It is designed for people with acute myeloid leukemia (AML) that has not responded to treatment or has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML that did not get better with treatment or has come back.
- You are 60 years old or younger.
- You have a stem cell donor who is a full sibling, unrelated match (9-10 out of 10 markers), or a half-matched family member.
- Your daily activities are not severely limited (ECOG score 0-2).
- You have not had a stem cell transplant before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a conditioning regimen (total marrow and lymphoid irradiation, fludarabine, and melphalan) before a donor stem cell transplant for people with high-risk myelodysplastic syndrome or acute myeloid leukemia. It aims to reduce side effects while still controlling the disease.
This trial is for people age 55 and older with high-risk acute myeloid leukemia (AML) who have already had a stem cell transplant. It tests a new combination of two drugs, Selinexor and Melphalan, given twice a week to help prevent the leukemia from coming back.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a gentler chemotherapy regimen before a stem cell transplant from a partially matched family donor for patients with acute myeloid leukemia (AML) who are older or have health conditions that make standard transplants risky. The goal is to help patients achieve long-term remission with fewer serious side effects.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.